Aurobindo Pharma shares fell 5.6 percent intraday Thursday on top of 3 percent loss seen in previous session after a media report indicated that the company named in a lawsuit for selling adulterated irbesartan products.
The Hyderabad-based drug major has been named in a class action lawsuit in the US for contamination of its irbesartan active ingredient (API).
Irbesartan active ingredient is used in the treatment of high blood pressure.
The latest lawsuit is a part of growing litigation against the makers and distributors of sartan-based blood pressure lowering drugs in the US, the report added.
For more details click here – https://www.ways2capital.com